Cedara Software, a division of Merge Healthcare, introduced a clutch of new products and services at the recent 2007 Radiological Society of North America (RSNA) conference in Chicago.
The company spotlighted its tools for application development including Open Eyes, available in Java and .NET platform for new development or as extensions to existing applications that incorporates connectivity, visualization and printing components.
MergeCOM3 was also on display and is a software development toolkit that provides abstraction of DICOM messaging details.
On the advanced visualization front, the company demonstrated its advanced segmentation technology that includes libraries for lesion contouring where tumor identification in ultrasound, CT and MRI is greatly simplified. It also showcased its Mammography Skinline detection for viewing mammography images and inverse rendering.
Cedara’s Image Enhancement was displayed and offers a complete x-ray pipeline workflow improvement from image enhancement, shutter detection and removal, auto-stitching and optimum window display. The company highlighted registration technology that offers unique registration for use in clinical packages that require rigid or deformable registration.
A new server-side rendering engine, Cedara ISG, was unveiled that is able to serve up 2D and 3D compressed images over the web and was demonstrated using a customized smart-client I-Response viewer. Cedara also showed a thin-client G6 viewer WIP that can run on Windows, Linux and Mac OS in standard web browsers.
The company also debuted its Cedara Clinical Control Center-enabled works-in-progress Cedara PET/CT module and Cedara I-Response for molecular imaging and cancer therapy.
The C4 PET/CT application was developed to follow radiology workflow and solve image fusion challenges in a PACS environment, according to Cedara.
The Cedara I-Response is designed to help evaluate, assess and monitor the effect of cancer therapy over time using data from multiple modalities. In addition to providing tools for standard anatomical measurements used for tumor assessment in cancer management and research, Cedara I-Response can analyze both PET/CT and MR-based diffusion-weighted imaging.
The company said that by providing the capability to visualize changes in tumors resulting from cellular and metabolic mechanisms during the course of treatment, the product provides clinically relevant information that potentially could be used to make mid-treatment therapy adjustments in an attempt to improve clinical outcome.
Cedara I-Response also features patented functional Diffusion Map technology based on work done at the University of Michigan. This functionality enables physicians to analyze DWI studies to visualize and quantify changes over time in the microscopic motion of water in healthy and diseased tissues.
The results of each analysis are included in automatically generated reports, as well as exported to file for import into a site’s existing data repositories. I-Response is available to original equipment manufacturers as a standalone workstation, and also can be integrated into existing PACS solutions using Cedara’s C4 integration platform.
In addition, the company’s custom engineering group discussed its development services. The group highlighted examples of positive return—ranging from successful collaborations with large R &D departments to serving as the entire development team for small start-up ventures.